NCT00703079View on ClinicalTrials.gov

Impact of Somatostatin Analogs vs. Surgery on Glucose Metabolism in Acromegaly

CompletedOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

January 31, 1997

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Acromegaly
Interventions
DRUG

Octreotide-LAR or lanreotide

Treated with octreotide-LAR will be given at dosages of 10-40 mg/q28d and treatment with lanreotide-SR at dosages of 60-120 mg/q28d. The dosages are up-titrated to control GH and IGF-I levels

PROCEDURE

Transsphenoidal adenomectomy

Removal of pituitary adenomas via one-nostril transsphenoidal approach and endoscopy-assisted.

Trial Locations (1)

80131

Department of Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples, Naples

All Listed Sponsors
lead

Federico II University

OTHER

NCT00703079 - Impact of Somatostatin Analogs vs. Surgery on Glucose Metabolism in Acromegaly | Biotech Hunter | Biotech Hunter